A 2-year prospective multicenter study of ultrasound cyclo plasty for glaucoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 06 2021
16 06 2021
Historique:
received:
22
03
2021
accepted:
29
05
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
5
11
2021
Statut:
epublish
Résumé
Ultrasound cyclo plasty (UCP) is a recently developed surgical technique for glaucoma allowing a selective and controlled coagulation of the ciliary body. We herein investigated the long-term efficacy and safety of UCP for the treatment of glaucoma. This prospective study included patients with primary and secondary glaucoma. All surgeries were performed using the EyeOP1 device (Eye Tech Care, Rillieux-la-Pape, France). Sixty-six patients were included, and 60 completed regularly the 2-year follow-up. Preoperative IOP was 28.5 ± 9.6 mmHg and significantly decreased to 17.0 ± 5.4 at 2 years (p < 0.001). The daily number of both hypotensive eye drops and acetazolamide tablets decreased significantly (respectively, from 2.6 ± 1.1 to 1.7 ± 1.2 and from 0.7 ± 0.8 to 0.2 ± 0.5; both p < 0.001). At 2 years, 68.1% of patients met the definition of qualified success (IOP < 21 mmHg regardless of glaucoma medications) and 10.3% of patients met the definition of complete success (IOP < 21 mmHg without glaucoma medications). No major intra- or postoperative complications occurred; however, 15 eyes required additional glaucoma surgery. These results suggest that UCP is an effective and safe procedure to reduce IOP in glaucoma patients through a 2-year follow-up period.
Identifiants
pubmed: 34135447
doi: 10.1038/s41598-021-92233-9
pii: 10.1038/s41598-021-92233-9
pmc: PMC8209230
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12647Références
Ophthalmic Res. 2019;61(3):137-142
pubmed: 29768281
J Vis Exp. 2018 Jan 26;(131):
pubmed: 29443031
Eur J Ophthalmol. 2021 Jan;31(1):130-137
pubmed: 31550914
Sci Rep. 2018 Jan 12;8(1):619
pubmed: 29330448
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Int J Ophthalmol. 2020 Jan 18;13(1):184-188
pubmed: 31956588
Br J Ophthalmol. 2002 Apr;86(4):381-6
pubmed: 11914203
Exp Eye Res. 2021 Apr;205:108506
pubmed: 33609512
Exp Eye Res. 1978 Aug;27(2):199-213
pubmed: 98338
Eur J Ophthalmol. 2015 Nov-Dec;25(6):483-9
pubmed: 25982212
Invest Ophthalmol Vis Sci. 2011 Nov 11;52(12):8747-53
pubmed: 21948551
Br J Ophthalmol. 2007 Dec;91(12):1631-5
pubmed: 17494956
Surv Ophthalmol. 2012 Jan-Feb;57(1):1-25
pubmed: 22137574
J Glaucoma. 2018 Sep;27(9):776-784
pubmed: 29781833
Acta Ophthalmol. 2016 Aug;94(5):e268-77
pubmed: 26547890
Eye (Lond). 2021 Feb;35(2):484-489
pubmed: 32317796
Acta Ophthalmol. 2015 Nov 19;94(5):e278-e286
pubmed: 26639735
Br J Ophthalmol. 2000 Sep;84(9):999-1003
pubmed: 10966953
J Glaucoma. 2020 Jun;29(6):407-408
pubmed: 32301765
Ophthalmology. 1990 Jan;97(1):69-72
pubmed: 2179798
Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5092-8
pubmed: 20484580
J Glaucoma. 2020 Jul;29(7):556-560
pubmed: 32217996
Curr Med Res Opin. 2014 Aug;30(8):1599-605
pubmed: 24689838
Int J Ophthalmol. 2019 Apr 18;12(4):597-602
pubmed: 31024813
Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):599-605
pubmed: 27915382
Invest Ophthalmol Vis Sci. 2015 Jan 20;56(2):1089-96
pubmed: 25604688